PubRank

Peter Rieckmann

Author PubWeight™ 76.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010 4.08
2 CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002 1.91
3 The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010 1.89
4 Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013 1.83
5 Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 2012 1.77
6 Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013 1.76
7 Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol 2011 1.69
8 EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet 2010 1.62
9 A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002 1.58
10 A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol 2003 1.57
11 Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 2002 1.53
12 A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005 1.50
13 New perspectives in the natural history of multiple sclerosis. Neurology 2010 1.50
14 Multiple sclerosis registry in Germany: results of the extension phase 2005/2006. Dtsch Arztebl Int 2008 1.33
15 Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler 2004 1.24
16 Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol 2005 1.19
17 Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. J Neuroimmunol 2010 1.12
18 Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 2011 1.11
19 Characteristic gene expression profile of primary human cerebral endothelial cells. FASEB J 2002 1.07
20 Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol 2005 1.05
21 Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2012 1.04
22 Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. J Neurooncol 2006 1.04
23 The natural history of primary progressive multiple sclerosis. Neurology 2009 1.02
24 Interferon-beta1b in multiple sclerosis. Expert Rev Neurother 2007 1.02
25 Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown. PLoS One 2010 1.00
26 Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 2002 0.99
27 Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011 0.98
28 Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls. J Neuroimmunol 2006 0.98
29 Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler 2011 0.97
30 Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. J Mol Med (Berl) 2005 0.96
31 Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. J Med Genet 2013 0.96
32 Early intervention in multiple sclerosis : better outcomes for patients and society? Drugs 2003 0.96
33 [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)]. Nervenarzt 2006 0.95
34 MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain 2013 0.94
35 Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration. J Neurochem 2007 0.94
36 Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 2008 0.94
37 Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosis. J Neurovirol 2006 0.94
38 Selective loss of regulatory T cells in thymomas. Ann Neurol 2004 0.94
39 Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer 2006 0.93
40 Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells. J Vasc Res 2006 0.92
41 Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol 2004 0.91
42 mtDNA nt13708A variant increases the risk of multiple sclerosis. PLoS One 2008 0.90
43 TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol 2007 0.88
44 Multiple sclerosis in the Arabian Gulf countries: a consensus statement. J Neurol 2013 0.88
45 Downregulation of CXCR1 and CXCR2 expression on human neutrophils by Helicobacter pylori: a new pathomechanism in H. pylori infection? Infect Immun 2004 0.87
46 Evidence for shoulder girdle dystonia in selected patients with cervical disc prolapse. Mov Disord 2002 0.87
47 Symptomatology of MS: results from the German MS Registry. J Neurol 2009 0.87
48 Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-up study. J Neurol 2004 0.86
49 Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci 2010 0.85
50 Imatinib buys time for brain after stroke. Nat Med 2008 0.85
51 Building up the blood-brain barrier. Nat Med 2003 0.84
52 MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol 2012 0.84
53 Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes. FEMS Immunol Med Microbiol 2003 0.83
54 Cytokine mRNA expression patterns in the disease course of female adolescents with anorexia nervosa. Psychoneuroendocrinology 2004 0.82
55 Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann N Y Acad Sci 2008 0.82
56 The Changes of P-glycoprotein Activity by Interferon-γ and Tumor Necrosis Factor-α in Primary and Immortalized Human Brain Microvascular Endothelial Cells. Biomol Ther (Seoul) 2012 0.81
57 Lack of immune responses against multiple sclerosis-associated retrovirus/human endogenous retrovirus W in patients with multiple sclerosis. J Neurovirol 2008 0.81
58 Functional role of ipsilateral motor areas in multiple sclerosis. J Neurol Neurosurg Psychiatry 2010 0.80
59 CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis. J Neuroimmunol 2002 0.80
60 Soluble Telencephalin in the serum of children after febrile seizures. J Neurol 2005 0.79
61 Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patients. Cytokine 2004 0.79
62 Excitability decreasing central motor plasticity is retained in multiple sclerosis patients. BMC Neurol 2012 0.79
63 Influence of VEGF-R2 inhibition on MMP secretion and motility of microvascular human cerebral endothelial cells (HCEC). J Neurooncol 2003 0.79
64 Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics 2014 0.79
65 Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada. Mult Scler 2012 0.78
66 Health outcomes in multiple sclerosis. Curr Opin Neurol 2004 0.78
67 Targeting progressive neuroaxonal injury: lessons from multiple sclerosis. CNS Drugs 2011 0.78
68 Brain derived neurotrophic factor does not act on adult human cerebral endothelial cells. Neurosci Lett 2002 0.77
69 Analysis of the stathmin rs182455 single nucleotide promoter polymorphism in patients with multiple sclerosis. J Neurogenet 2008 0.77
70 Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study. Clin Drug Investig 2012 0.76
71 UM 9(5)h and UM 9(5)p, human and porcine noncoding transcripts with preferential expression in the cerebellum. RNA 2002 0.76
72 Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord 2012 0.75
73 Re: Errors in the editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670-1672]. Mult Scler 2013 0.75
74 sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot study. J Neurol 2002 0.75
75 The blood-brain barrier as target of multiple sclerosis research and therapy. Report of an international scientific meeting, Würzburg, January 23/24, 2004. J Neuroimmunol 2004 0.75
76 [Practical advice for a safe, effective and well tolerated therapy of multiple sclerosis]. MMW Fortschr Med 2006 0.75
77 The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MS. J Neuroimmunol 2004 0.75